IM-1021
Topline/data readout2026
Stage: Not stated
Public float: $728,500,000 · as of · SEC filing
initial lymphoma data for IM-1021 in 2026
10-Q · Filed · Last checked
Source details
Alert me · Calendar: same stage and window-end month (2026-12)
Immunome (IMNM) pipeline and stated timing
Name in SEC filings: Immunome Inc.
Pipeline at a glance
| Program | Event | Stage | Stated timing | Filing |
|---|---|---|---|---|
| IM-1021 | /data readout | Stage not stated | 2026 | 10-Q · |
| varegacestat | target date (company stated) | PDUFA | April 28, 2027 | SEC filing · |
Source: ORION, orionbiotechai.com/company/IMNM, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/IMNM
IM-1021 · Topline/data readout · 2026
SEC sources last checked .
Programs and stated timing
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
Matched
varegacestat
desmoid tumors in adults
PDUFA target date (company stated)April 28, 2027
Stage: PDUFASEC filing · “PDUFA, target action date”
Public float: $728,500,000 · as of · SEC filing
Prescription Drug User Fee Act, or PDUFA, target action date of April 28, 2027
SEC filing · Filed · Last checked
Source details
Alert me · Calendar: same stage and window-end month (2027-04)
How this date was described over time
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| IM-1021Clinical results | 2026“initial lymphoma data for IM-1021 in 2026” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| varegacestatFDA decision | April 28, 2027“Prescription Drug User Fee Act, or PDUFA, target action date of April 28, 2027” Filed · SEC original | Period not started The stated period has not started yet, so there is nothing to compare. |
| varegacestatFDA decision | April 28, 2027“PDUFA target action date of April 28, 2027” Filed · SEC original | Period not started The stated period has not started yet, so there is nothing to compare. |
| varegacestatFDA decision | April 28, 2027“PDUFA date of April 28, 2027” Filed · SEC original | Period not started The stated period has not started yet, so there is nothing to compare. |
| varegacestatFDA decision | April 28, 2027“PDUFA target action date set for April 28, 2027” Filed · SEC original | Period not started The stated period has not started yet, so there is nothing to compare. |
| varegacestatFDA decision | April 28, 2027“PDUFA target action date of April 28, 2027” Filed · SEC original | Period not started The stated period has not started yet, so there is nothing to compare. |
| IM-1021Clinical results | 2026“initial lymphoma data in 2026” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| IM-1021Clinical results | 2026“initial lymphoma data for IM-1021 in 2026” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| IM-1021Clinical results | 2026“lymphoma data expected in 2026” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| IM-1021Clinical results | 2026“initial lymphoma data for IM-1021 in 2026” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| IM-1021Clinical results | 2026“lymphoma patients treated with IM-1021, and we plan to share initial data in 2026” Filed · 10-K | Still within period As of Oct 19, 2026 |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
Retained company announcements
Historical summaries and source dates are retained separately from the SEC timing quotes above. Earlier publications were collected retrospectively.
Historical catalog checked .
No historical announcement trail is retained for this company in this catalog.
Selected registry record
IM-1617 · NCT07578571
- Condition in the selected registry record
- Colorectal Cancer
- Phase in the selected registry record
- Phase 1
- Identity checked
Original ClinicalTrials.gov record · Open the selected study
Retained company–study identity sources
Scope of retained company and registry evidence
These are selected linked records and dated source metadata, not a live registry recheck or the company’s full pipeline. Company announcements and the selected registry study are separate evidence sets. No stage or event timing is borrowed between them.
Coverage and identity checksWatch IMNM
Request another SEC timing statement
Suggest an SEC timing statement to add for IMNM. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.
Reading these records
- First stated window
- The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
- Disclosure date
- The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
- 1H, 2H, 1Q–4Q
- First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
- SEC original
- The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
- Status
- One of seven labels set by founder review of the original filings. Definitions: Methodology.
See IMNM in the calendar · Review labels and methodology
Topline results are the main summary results of a clinical trial, released before the full data.A PDUFA date is the target date by which the FDA aims to decide on a drug or biologic application.